DISCOVERING TOMORROW'S DRUGS WITH ARTIFICIAL INTELLIGENCE
Kantify uses Artificial Intelligence to discover breakthrough therapies that change patients' lives.
Our cutting-edge AI platform, Zeptomics, identifies promising drugs in silico, with lightning speed, for any disease target.
Our cutting-edge AI platform, Zeptomics, identifies promising drugs in silico, with lightning speed, for any disease target.
Drugging the undruggable
95% of diseases still do not have a therapy. Our purpose is to propel the discovery of new therapies where patients are still expecting them.Kantify's AI technology Zeptomics is an accelerator to discover effective and safe drugs, with unprecedented performance. Zeptomics can be used for any indication. It is currently focusing on small molecule drugs and targeted protein degraders.
A leap forward in drug discovery
Extremely accurate
Zeptomics is unique in its capacity to predict promising molecules for a given target. Its hit rates are between 28% and 67%.Disease agnostic
Zeptomics has the capacity to discover promising drugs for any target. It makes it a useful tool for novel or under researched targets.Mitigate Risks
Zeptomics also predicts off target effects and ADMET properties, amongst others. It decreases the risk to fail.Uniquely capable
Because Zeptomics unlocks the bottleneck of identifying the right targets for a disease it provides a significant step ahead in drug discovery.Platform
Zeptomics is a deep learning based platform relying on proprietary models. Because it is already trained on a unique dataset of 120 million data points, it does not need initial data to be ignited. Give Zeptomics a protein sequence and let it provide predictions.
Pipeline
We are developing a pipeline of small molecules and degraders in neurology, neuromuscular diseases, cardiology and oncology. We collaborate with world class experts to discover promising molecules.
Company
We are a mission driven company at the crossroads of Artificial Intelligence and Biotechnology. We have strong values and use our brains to make a difference in patients' lives. Discover our journey and how to join our team.
Partnership
Kantify believes in the power of partnerships. We bring unique in silico predictions to our partners to advance together. Discover how to partner with Kantify and accelerate or unlock your drug hunting project.
Wed 29 Nov 2023
Kantify will use its AI platform to tackle 5 rare diseases
Kantify is selected by the European Commission to perform an unprecedented research project on rare diseases and AI
Thu 05 Oct 2023
Kantify speaking at Slush'D Leuven
Kantify will be speaking in the panel on "AI: redefining business or enhancing roles"
Tue 05 Sep 2023
AI for selectivity and polypharmacology of small molecules
Off-target effects can be an essential component of a small molecule's clinical success or failure. With AI, these relationships can be identified and leveraged
Thu 17 Aug 2023
AI and Drug Repurposing: Farewell, serendipity?
Our pledge to make therapies available for patients, faster, and why Artificial Intelligence is the key for small molecule repurposing